Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia Authors: Aziz Farhat, Georgina El Hajjar, Hagop Kantarjian, Koji Sasaki, Nicholas J. Short, Branko Cuglievan, Sanam Loghavi, Keyur Patel, Alex Bataller, Wei Ying Jen, Musa Yilmaz, Guillermo Montalban‐Bravo, Danielle Hammond, Naveen Pemmaraju, Naval Daver, Farhad Ravandi, Elias Jabbour, Tapan Kadia, Gautam Borthakur, Guillermo Garcia‐Manero, Courtney D. DiNardo, Ghayas C. Issa Published: 2026 ABSTRACT AbstractBackgroundNucleophosmin 1‐mutated (NPM1mt) acute myeloid leukemia (AML) is associated with a relatively favorable prognosis though long‐term outcomes remain suboptimal without clear predictors identified by therapy.MethodsIn a retrospective analysis, the authors identified 396 patients (18%) with newly diagnosed (ND) NPM1mt AML treated at The University of Texas MD Anderson Cancer Center and analyzed their outcomes. Using a Cox regression model, they analyzed predictors of survival in newly diagnosed NPM1mt AML across various therapies.ResultsThose treated with high intensity chemotherapy had a median overall survival (OS) of 84.7 months with a 5‐year rate of 53% (95% CI, 44%–61%) whereas those treated with a combination of a hypomethylating agent (HMA) and venetoclax had a median OS of 23.3 months with a 5‐year rate of 19% (95% CI, 5%–39%). The combination of cladribine, low‐dose cytarabine, and venetoclax alternating with azacitidine and venetoclax yielded better survival compared with HMA and venetoclax in an age‐matched analysis (5‐year OS rate of 74% vs. 24%) (p = .048).ConclusionAmong patients with NPM1mt treated with high‐intensity chemotherapy, older age, a poor performance status, and presence of a FLT3‐ITD mutation or extramedullary disease predicted a worse overall survival. For patients treated with a hypomethylating agent and venetoclax, older age was the only predictor of worse long‐term outcomes. These findings can be used for risk‐stratification of newly diagnosed NPM1mt AML and provide benchmarks of response and survival for this subtype. INTRODUCTION Although nucleophosmin 1 mutation (NPM1mt) is considered as a favorable risk acute myeloid leukemia (AML) alteration by European LeukemiaNet (ELN) guidelines, 1 , 2 long‐term outcomes remain suboptimal, especially in older adults who are unable to receive high intensity chemotherapy. 3 , 4 NPM1mt form the most common alteration in AML detected in up to 30% of cases. 3 , 5 There is a need to optimize therapeutic strategies for this molecular subset and improve chances of cure. Prognosis in NPM1mt AML is dependent on comutations, with a clear impact of measurable residual disease detection on long‐term outcomes. 4 , 6 In addition, NPM1mt occur in leukemia founding clones and is considered an AML defining event, given the near exclusive detection in this setting but not in other malignancies or premalignant conditions. 7 , 8 NPM1mt lead to a cytoplasmic translocation of this nucleolar protein, with a fraction remaining in the nucleolus and directly interacting with epigenetic regulators that cause altered gene expression and leukemia. 9 , 10 With the advent of menin inhibitors as an epigenetic therapy reversing this aberrant gene expression, multiple clinical trials are ongoing or planned to test the addition of this promising therapy to frontline AML treatments. 11 , 12 , 13 However, the full spectrum of prognostic factors in NPM1mt AML and expected outcomes by therapy have not been fully elucidated. In this study, we performed a retrospective analysis to identify clinical and molecular predictors of survival in patients with NPM1mt AML, aiming to inform future therapeutic strategies and guide risk‐adapted approaches. MATERIALS AND METHODS Patients We identified 2215 patients with newly diagnosed AML with molecular characterization treated at our center between January 2012 and December 2023, of whom 396 (18%) had NPM1mt. Treatment consisted of either high‐ or low‐intensity regimens based on age and comorbidities. High‐intensity regimens included combinations of cytarabine and idarubicin with or without a second nucleoside analog (i.e., cladribine, fludarabine, or clofarabine). 14 , 15 Venetoclax was added to high‐intensity chemotherapy in subsequent trials. 16 , 17 Low‐intensity regimens included either a hypomethylating agents (i.e., azacitidine or decitabine) or low‐dose cytarabine, with the addition of venetoclax, or the addition of venetoclax to cladribine and low‐dose cytarabine alternating with azacitidine (Clad + LDAC + Ven). 18 Measurable residual disease (MRD) assessment was performed on bone marrow samples using multicolor flow cytometry as previously described, with a predicted sensitivity of 10‐4. 19 Targeted next‐generation sequencing was performed using panels of genes recurrently mutated in leukemia. 20 Molecular MRD assessment and variant allele frequency (VAF) data were not available. This study was done in accordance with the Declaration of Helsinki and was approved by the institutional review board. Statistical methods Patient characteristics were summarized using medians and ranges for continuous variables and frequencies or percentages for categorical variables. Continuous variables were compared using the Wilcoxon rank‐sum test for pairwise comparisons and the Kruskal–Wallis for multiple comparisons. Categorical variables were compared using Fisher exact test. Responses were defined according to European LeukemiaNet classification. 1 Overall survival (OS) was calculated from the time of diagnosis to the time of death or last follow‐up. Event‐free survival (EFS) was defined as the duration from the initiation of treatment until either failure of achieving a complete remission at day 56, disease relapse, or death from any cause, whichever occurred first, following the Food and Drug Administration guidance for this definition. The Kaplan–Meier method was used to estimate the probability of OS or EFS and was compared by the log‐rank test. Univariate and multivariate Cox proportional hazards models were used to assess the association between patient characteristics and outcomes where factors with p < .1 on univariate analysis selected for the multivariate. Analyses were performed using GraphPad Prism (San Diego, California, USA) and IBM SPSS Statistics version 24 (Armonk, New York, USA). RESULTS Baseline characteristics Patients with NPM1mt had a median age of 64 years (range, 17–88) and were more likely to be female (56% vs. 43% in the NPM1wt group; p < .001) (Table 1). NPM1mt was associated with higher percentages of bone marrow and peripheral blood blasts (p < .001), highlighting a more proliferative disease biology. Morphologically, NPM1mt patients frequently exhibited myelomonocytic or monocytic features, seen in 40% compared to only 15% of NPM1wt cases (p < .001), suggesting a phenotypic pattern often associated with this mutation. As previously described, 75% of patients with NPM1mt had a diploid karyotype versus 24% in the NPM1wt cohort (p < .001). Additionally, the presence of myelofibrosis of grade 1 or higher was more prevalent among NPM1mt patients (30% vs. 23%; p = .003). Extramedullary involvement was noted in 3% of NPM1mt cases including skin, soft tissue, and lymph node involvement (Supporting Information S1: Table S1). TABLE 1Baseline characteristics.Characteristic NPM1mt (n = 396) NPM1wt (n = 1819) p Median age, years (range)64 (17–88)65 (18–94).5Female sex, No. (%)220 (56)776 (43)<.001BM blasts %, median (range)61 (3–97)37 (0–99)<.001PB blasts %, median (range)24 (0–99)9 (0–98)<.001WBC count, median ×109/L (range)4.7 (0.2–378.4)3.5 (0.1–250)<.001Platelet count, median ×109/L (range)34 (1–1306)37 (1–1069).1Myelomonocytic or monocytic, No. (%) c 159 (40)280 (15)<.001Therapy‐related AML, No. (%)37 (9)337 (19)<.001Diploid karyotype, No. (%)295 (75)430 (24)<.001Complex karyotype, No. (%)14 (4)605 (33)<.001Extramedullary involvement, No. (%)14 (3)44 (2).2Bone marrow fibrosis, No. (%) a 118 (30)417 (23).003No. of mutations/patient, mean; σ (range)2.3;1.3 (0–8)1.8;1.5 (0–8)<.001Comutations DNMT3A 156/332 (47)230/1264 (18)<.001 FLT3‐ITD 166/353 (47)232/1373 (17)<.001 N/KRAS 89/312 (29)336/1343 (25).2 TET2 62/287 (22)171/1255 (14).001 FLT3‐TKD 61/344 (18)115/1356 (7)<.001 PTPN11 45/274 (16)91/1132 (8)<.001 IDH1 48/297 (16)101/1247 (8)<.001 IDH2 92/311 (30)193/1267 (15)<.001Myelodysplasia‐related genes b 47/349 (13)461/1560 (30)<.001 WT1 20/236 (9)89/989 (9).9 TP53 11/290 (4)393/1383 (28)<.001 Note: Comparisons between groups using Kruskal–Wallis, Fisher exact, and χ2 tests.Abbreviations: BM, bone marrow; PB, peripheral blood; WBC, white blood cells. a MF‐1 grade or higher. b Myelodysplasia‐related genes include ASXL1, BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, ZRSR2, and RUNX1. c Myelomonocytic/monocytic features were defined according to FAB AML classification or based on available information in the pathology report. Baseline characteristics. Note: Comparisons between groups using Kruskal–Wallis, Fisher exact, and χ2 tests. Abbreviations: BM, bone marrow; PB, peripheral blood; WBC, white blood cells. MF‐1 grade or higher. Myelodysplasia‐related genes include ASXL1, BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, ZRSR2, and RUNX1. Myelomonocytic/monocytic features were defined according to FAB AML classification or based on available information in the pathology report. On the molecular level, NPM1mt AML patients had a higher mean number of mutations per patient compared with NPM1wt AML patients (2.3 vs. 1.8, p < .001) (Table 1). Distinct mutational landscapes also emerged (Table 1). DNMT3A mutations were highly enriched in the NPM1mt group (47%) compared to 18% in NPM1wt (p < .001). Likewise, FLT3‐ ITD mutations were also more frequent among NPM1mt patients (47% vs. 17%; p < .001). In contrast, N/KRAS mutations were similarly distributed (29% in NPM1mt vs. 25% in NPM1wt; p = .2), whereas TET2 mutations appeared more often in NPM1mt (22% vs. 14%; p < .001). Other adverse risk co‐occurring mutations were less common. TP53 mutations, for instance, were detected in only 4% of NPM1mt cases (11 patients) versus 28% of NPM1wt patients (393 patients) (p < .001). Similarly, mutations linked to myelodysplasia were much more frequent in NPM1wt—affecting 25% (461 patients) versus only 12% (47 patients) in the NPM1mt cohort (p < .001) (Table 1). Specifically, mutations in ASXL1, BCOR, EZH2, RUNX1, STAG2, and U2AF1 were all significantly less common in the NPM1mt group (Supporting Information S1: Tables S2, S3, and S8). Response of NPM1mt AML to frontline therapies Newly diagnosed patients with NPM1mt AML exhibited significantly superior response rates compared to those with NPM1wt. The complete remission (CR) rate, regardless of the frontline therapy used, was 76% for those with NPM1mt AML versus 58% for those with the wildtype gene (p < .001) (Table 2). In addition, NPM1mt was associated with a lower rate of early mortality (60‐day mortality of 8% vs. 12% for NPM1wt, p = .02). This cohort included 142 patients with NPM1mt (36%) treated with high‐intensity chemotherapy without venetoclax, 32 patients (8%) treated the combination of cladribine, cytarabine and venetoclax alternating with azacitidine and venetoclax (Clad + LDAC + Ven), and 67 patients treated with a hypomethylating agent and venetoclax (17%). Patients who received high‐intensity chemotherapy had a CR rate of 88% and a composite CR rate (CR + CRi = CRc) of 94% with MRD negativity in this subset of 89% by MFC. Those with NPM1mt AML who received Clad + LDAC + Ven had a CR rate of 85% and a CRc rate of 97% with MRD negativity of 97% by MFC (Supporting Information S1: Table S4). Patients who received a hypomethylating agent and venetoclax had a CR rate of 80% and a CRc rate of 86% and MRD negativity in this subset of 88% by MFC (Supporting Information S1: Tables S4 and S9). Forty‐six patients received high‐intensity chemotherapy with the addition of venetoclax (12%). 16 , 17 This cohort had similar response rates as patients who received high‐intensity chemotherapy without venetoclax, with a CR rate of 87% and a CRc rate of 96% with MRD negativity in this subset of 84% by MFC (Supporting Information S1: Table S4). TABLE 2Responses and early mortality following first‐line therapy.Response NPM1mt (n = 396), No. (%) NPM1wt (n = 1819), No. (%) p CR302 (76)1054 (58)CRi35 (10)180 (10)CRc337 (86)1234 (68)<.001MRD a neg in CRc b 277/306 (90)683/1234 (55)<.001MLFS13 (3)73 (3)PR1 (0)23 (1)NR25 (6)308 (17)<.001NE16 (4)27 (8)Death before evaluation16 (4)153 (8)30‐day mortality17 (4)107 (6).260‐day mortality32 (8)221 (12).023Abbreviations: CR, complete remission; CRi, complete remission with incomplete count recovery; CRc, composite complete remission; MLFS, morphologic leukemia‐free state; MRD, measurable residual disease; NE, not evaluable; NR, no response; PR, partial remission. a MRD measured by multicolor flow cytometry with predicted sensitivity of 10‾4. b Denominator reflects patients who achieved CRc and had available MRD data. Responses and early mortality following first‐line therapy. Abbreviations: CR, complete remission; CRi, complete remission with incomplete count recovery; CRc, composite complete remission; MLFS, morphologic leukemia‐free state; MRD, measurable residual disease; NE, not evaluable; NR, no response; PR, partial remission. MRD measured by multicolor flow cytometry with predicted sensitivity of 10‾4. Denominator reflects patients who achieved CRc and had available MRD data. Survival outcomes of NPM1mt AML with frontline therapies With a median follow‐up of 52.6 months, NPM1mt patients treated with high‐intensity chemotherapy had a median event‐free survival (EFS) of 84.7 months, with a 5‐year EFS of 52% (95% CI, 44%–60%) whereas the median OS was 88.8 months with a 5‐year OS rate of 55% (95% CI, 46%–2%) (Figure 1). The addition of venetoclax to high‐intensity chemotherapy (N = 46 patients) resulted in a 2‐year EFS and OS rates of 65% (95% CI, 48%–72%) and 71% (95% CI, 54%–84%) versus 58% (95% CI, 50%–66%) and 65% (95% CI, 55%–72%), respectively, without venetoclax (p = .5, p = .4) (Figure 2) with similar outcomes when stratifying patients by FLT3‐ITD comutation (Supporting Information S1: Figure S1). However, it is important to note the smaller numbers in this subgroup analysis and the relatively shorter follow‐up duration in the venetoclax arm. Survival outcomes of newly diagnosed NPM1‐mutant AML by therapy. (A) EFS and OS in patients treated with high‐intensity chemotherapy, or (B) with the combination of cladribine, low‐dose cytarabine and venetoclax alternating with azacitidine and venetoclax, or (C) with a hypomethylating agent and venetoclax. AML indicates acute myeloid leukemia; Clad + LDAC + Ven, cladribine, low dose cytarabine, and venetoclax; EFS, event‐free survival; HMA + Ven, hypomethylating agent and venetoclax; OS, overall survival. Survival outcomes of newly diagnosed NPM1‐mutant AML treated with high‐intensity chemotherapy, with and without the addition of venetoclax. (A) Event‐free survival. (B) Overall survival. AML indicates acute myeloid leukemia. The Clad + LDAC + Ven regimen is used at our center for patients with age >60 years or for those unable to received high‐intensity chemotherapy. 18 This regimen resulted in 5‐year EFS and OS rates of 66% (95% CI, 46%–80%) and 72% (95% CI, 52%–85%), respectively (N = 32 patients) (Figure 1). In contrast, treatment with HMA + Ven resulted in 5‐year EFS and OS rates of 12% (95% CI, 1%–33%) and 19% (95% CI, 5%–39%), respectively (N = 67 patients) (Figure 1). Given that the median age of patients treated with Clad + LDAC + Ven was lower than those treated with HMA + Ven, we compared survival between these two regimens following age matching of patients. In the age‐matched analysis, Clad + LDAC + Ven continued to demonstrate superior EFS and OS compared with HMA + Ven with 5‐year rates of 68% (95% CI, 47%–82%) and 74% (95% CI, 53%–87%) versus 15% (95% CI, 1%–41%) and 24% (95% CI, 5%–49%), respectively (p = .002; p = .048) (Supporting Information S1: Figure S2; Table S5). Notably, similar rates of transplant were observed in these two age‐matched arms with 11 of 32 patients (34%) transplanted following Clad + LDAC + Ven versus eight of 32 patients (25%) following HMA + Ven. Given prioritization of FLT3‐inhibitor triplet based therapies at our institution, fewer patients with FLT3‐ITD comutation were treated with Clad + LDAC + Ven, and all had low allelic burdens (N = 5, 16% of Clad + LDAC + Ven) or HMA + Ven (N = 22, 33% of HMA + Ven) compared with high‐intensity regimens included in this cohort (N = 94, 50% of HI) that also likely explains variability in outcomes (Supporting Information S1: Figure S3). For patients older than 75 years of age, the median EFS and OS for NPM1mt AML were 1.9 months and 10.4 months, respectively (N = 38 patients) (Figure 3). Survival outcomes of newly diagnosed NPM1‐mutant AML treated with a hypomethylating agent and venetoclax by age. (A) Event‐free survival. (B) Overall survival. AML indicates acute myeloid leukemia; HMA + Ven, hypomethylating agent and venetoclax. Among 396 patients with NPM1mt AML, 120 underwent allogeneic stem cell transplantation (SCT), with a median time to transplant of 130 days from diagnosis. Eighty‐nine of them were treated with high intensity chemotherapy with or without venetoclax with a median time to transplant of 129 days from diagnosis. This time was used in a landmark analysis comparing outcomes with and without SCT that demonstrated no difference in survival with 5‐year OS rates of 59% versus 65% in the nontransplant cohort (p = .4) (Supporting Information S1: Figure S4A). There was no significant difference in survival when stratifying by age <60 years at diagnosis or FLT3‐ITD or FLT3‐TKD comutation (Supporting Information S1: Figure S4B,C). To further investigate this trend, a time‐dependent analysis was performed using the Simon‐Makuch method. No significant difference in survival was observed for patients who received high intensity chemotherapy with or without transplantation. (Supporting Information S1: Figure S5) Predictors of EFS and OS in newly diagnosed NPM1mt AML On univariate analysis among patients with NPM1mt who received high‐intensity chemotherapy, predictors of worse EFS and OS included older age (hazard ratio [HR] for OS, 1.02; p = .018), FLT3‐ITD (HR for OS, 1.6; p = .045), EMD (HR for OS, 4.4; p = .002), and a performance status >2 (HR for OS, 7.7; p = .001 and for EFS, 11; p = .001). In a multivariate analysis, predictors of worse EFS and OS included older age (HR for OS, 1.03; p = .029), FLT3‐ITD (HR for OS, 2.1; p = .004), EMD (HR for OS, 8.9; p < .001, for EFS, 2.5; p = .05), and a PS >2 (HR for OS, 9.8; p < .001 and for EFS, 11.7; p < .001) (Figure 4; Supporting Information S1: Table S6). Predictors of outcomes in newly diagnosed NPM1‐mutant AML by therapy using univariate and multivariate analyses. (A) High‐intensity chemotherapy. (B) Hypomethylating agent and venetoclax. AML indicates acute myeloid leukemia; EMD, extramedullary disease; MF, myelofibrosis; PS, performance status; # mut, number of co‐occurring mutations. Among patients with NPM1mt who received HMA + Ven, the univariate analysis identified older age (HR for OS, 1.08; p = .002), complex karyotype (HR for OS, 3.6; p = .016), myelofibrosis grade 1 or more (HR for OS, 2.1; p = .027), increased number of comutations (HR for OS, 1.3; p = .025), and mutated TP53 (HR for OS, 10.2; p = .006) as worse prognostic factors for OS. However, in the multivariate analysis, only age emerged as an independent adverse prognostic factor for OS (HR for OS, 1.1; p = .01) (Figure 4; Supporting Information S1: Table S7). DISCUSSION This analysis highlights the unique clinical and molecular landscape of NPM1mt AML, emphasizing favorable prognostic features albeit some underlying heterogeneity within this subset. Although NPM1mt mutations are typically associated with a good prognosis, outcomes vary considerably based on comutations, patient performance status, and treatment strategy. Patients with NPM1mt AML in our cohort demonstrated a predominance of diploid cytogenetics, proliferative features, and lower frequencies of high‐risk alterations such as TP53 mutations or myelodysplasia‐related gene mutations—consistent with prior characterizations of this biologically distinct subgroup. 4 The main limitation of this analysis is related to the retrospective, single‐center design, with a variety of treatments tested, therefore, results should be interpreted with caution The relatively low proportion of patients with NPM1mt AML in our cohort likely reflects the referral patterns at our institution, which enrich for patients with adverse‐risk disease, including TP53mt and therapy‐related AML. This referral bias may have contributed to the lower observed frequency of NPM1mt AML within the studied population. Despite these generally favorable markers, our findings illustrate that age and treatment choice remains as major determinant of clinical outcomes. These findings are especially relevant for older adults or those unfit for intensive therapy, for whom Clad + LDAC + Ven may represent a more effective and tolerable option, which could be attributed to a particular susceptibility of NPM1mt AML to cytarabine, or abrogation of the adverse impact of the monocytic phenotype by the addition of cladribine. 21 However, the number of patients in each subgroup is relatively small and prospective studies are needed to confirm this observation. Among patients receiving high‐intensity chemotherapy, several factors were independently associated with inferior survival. These included older age, FLT3‐ITD, extramedullary disease, and performance status >2, all of which align with established markers of poor prognosis. In contrast, for the HMA + Ven cohort, age was the only variable that retained prognostic significance in multivariate analysis. Notably, adverse features such as complex karyotype, myelofibrosis, and the number of comutations—including TP53—did not demonstrate a significant impact in this setting which could be related also to smaller numbers in each subset. The consistent effect of older age across treatment strategies also supports prior findings of reduced tolerance and resistance to therapy in older patients. 22 , 23 The prognostic role of MDS‐related mutations in N PM1mt AML remains unclear. In our cohort, these mutations did not show a significant association with outcomes across treatment regimens. According to ELN 2022 guidelines, the presence of MDS‐related mutations does not override favorable‐risk features such as isolated NPM1 mutation. 1 This is consistent with some studies reporting no prognostic effect, 24 , 25 , 26 , 27 although others have suggested a negative impact. 28 , 29 Recent HARMONY studies have provided a more detailed evaluation of these effects. Findings from the HARMONY Alliance indicate that MDS‐related mutations are associated with inferior outcomes in FLT3 ‐ITD/NPM1 wild‐type AML, but not in NPM1‐mutated disease. 30 Additional analyses from the same collaborative effort demonstrated that individual MDS‐related mutations exert variable prognostic effects in NPM1mt AML, with RUNX1 associated with adverse outcomes, SRSF2 with intermediate prognosis, and STAG2 with favorable outcomes in the absence of FLT3 ‐ITD. 31 Collectively, these findings suggest that MDS‐related mutations do not confer a uniform prognostic impact in NPM1mt AML, but rather influence outcomes in a mutation‐specific and context‐dependent manner. In our cohort, MDS‐related mutations were not significantly associated with outcomes; however, this observation may be limited by the small sample size and incomplete availability of genetic testing data. Overall, the heterogeneity of reported results indicates that the prognostic significance of MDS‐related mutations is likely context‐ and therapy‐dependent and should therefore be interpreted with caution. Outcomes with high‐intensity chemotherapy in NPM1mt AML were affected by presence of FLT3‐ITD, or extramedullary disease, or poor performance status, whereas these factors were less impactful in the HMA + Ven, which could be attributed to a smaller cohort size, in addition to biologic or therapy related factors. It is important to note that regardless of therapy used, the chances of response, including MRD negative remissions by flow cytometry in NPM1mt AML were high, nearing 90%. Therefore, future studies designed with a response or MRD end point for NPM1mt AML should use more sensitive MRD methods (as opposed to flow cytometry), such as polymerase chain reaction or next‐generation sequencing‐based to discriminate improvement in depth of remission with the addition of investigational agents. Our findings offer valuable real‐world insights to guide treatment decisions as well as trial design and emphasize the need for prospective studies to optimize therapeutic strategies for NPM1mt AML. AUTHOR CONTRIBUTIONS Aziz Farhat: Formal analysis and writing–original draft. Georgina El Hajjar: Formal analysis and writing–original draft. Hagop Kantarjian: Writing–review and editing. Koji Sasaki: Writing–review and editing. Nicholas J. Short: Writing–review and editing. Branko Cuglievan: Writing–review and editing. Sanam Loghavi: Writing–review and editing. Keyur Patel: Writing–review and editing. Alex Bataller: Writing–review and editing. Wei Ying Jen: Writing–review and editing. Musa Yilmaz: Writing–review and editing. Guillermo Montalban‐Bravo: Writing–review and editing. Danielle Hammond: Writing–review and editing. Naveen Pemmaraju: Writing–review and editing. Naval Daver: Writing–review and editing. Farhad Ravandi: Writing–review and editing. Elias Jabbour: Writing–review and editing. Tapan Kadia: Writing–review and editing. Gautam Borthakur: Writing–review and editing. Guillermo Garcia‐Manero: Writing–review and editing. Courtney D. DiNardo: Writing–review and editing. Ghayas C. Issa: Writing–original draft, supervision, and formal analysis. All authors read and approved the final version of the manuscript. CONFLICT OF INTEREST STATEMENT Hagop Kantarjian has received research funding from AbbVie, Amgen, Ascentage Pharma, BMS, Daiichi Sankyo, ImmunoGen, Jazz Pharmaceuticals, and Novartis as well as honoraria from AbbVie, Amgen, Amphista Therapeutics, Ascentage Pharma, Astellas Pharma, Biologix, Curis, Ipsen, KAHR, Novartis, Pfizer, Precision Biosciences, Shenzhen TargetRx, and Takeda Oncology. Koji Sasaki reports fees for professional activities from Amgen, Chugai Pharmaceutical, Daiichi Sankyo Company, Novartis, Otsuka Pharmaceutical Co., Ltd, and Pfizer. Nicholas J. Short has been a consultant for Takeda Oncology, AstraZeneca, Amgen, Novartis, and Pfizer and received research funding from Takeda Oncology, Astellas, and Stemline Therapeutics as well as honoraria from Amgen. Sanam Loghavi reports consultant/advisory fees from Guidepoint, QualWorld, Gerson Lehrman Group, AbbVie, Daiichi Sankyo, BluePrint Medicine, Caris Diagnostics, Recordati, VJ HemeOnc, AlphaSight, and Arima; honoraria from OncLive, PeerView, MD Education, VJ HemeOnc, NCCN, MashUp Media, Binay Foundation, and American Society of Hematology; and stock in AbbVie. Musa Yilmaz has received research funding from Daiichi‐Sankyo and Pfizer. Naval Daver has received research funding from Astellas Pharma, AbbVie, Genentech, Daiichi Sankyo, Gilead Sciences, ImmunoGen, Pfizer, Bristol‐Myers Squibb, Trovagene, Servier, Novimmune, Incyte, Hanmi Pharm, Fate Therapeutics, Amgen, Kite Pharma, Novartis, Astex Pharmaceuticals, KAHR, Shattuck, Sobi, GlycoMimetics, and Trillium; has been an advisor for Astellas Pharma, AbbVie, Genentech, Daiichi Sankyo, Novartis, Jazz Pharmaceuticals, Amgen, Servier, Karyopharm Therapeutics, Trovagene, Trillium, Syndax, Gilead Sciences, Pfizer, Bristol‐Myers Squibb, Kite Pharma, Actinium Pharmaceuticals, Arog Pharmaceuticals, ImmunoGen, Arcellx, and Shattuck; has been a data monitoring committee member for Kartos Therapeutics and Jazz Pharmaceuticals; has been a consultant or board of directors or advisory committee member for Agios, Celgene, Sobi, and STAR Therapeutics; and has received research funding from Karyopham Therapeutics and Newave Pharmaceutical. Farhad Ravandi has received research funding from Amgen, Astex Pharmaceuticals/Taiho Oncology, BMS/Celgene, Syos, AbbVie, Prelude, Xencor, Astellas Pharma, and Biomea Fusion; has received honoraria from Amgen, BMS/Celgene, Syos, AbbVie, and Astellas Pharma; has been a board of directors or advisory committee member for Astex Pharmaceuticals/Taiho Oncology; and has been a consultant for BMS/Celgene, Syos, Novartis, AbbVie, AstraZeneca, and Astellas Pharma. Elias Jabbour has been a consultant for AbbVie, Adaptive Biotechnologies, Amgen, Bristol‐Myers Squibb, Novartis, Pfizer Canada Inc, and Takeda Oncology. Tapan Kadia has been a consultant for AbbVie, Agios, BMS, Genentech, Jazz Pharmaceuticals, Novartis, Servier, and PinotBio; has received research funding from AbbVie, BMS, Genentech, Jazz Pharmaceuticals, Pfizer, Cellenkos, Ascentage Pharma, GenFleet Therapeutics, Astellas Pharma, AstraZeneca, Amgen, Cyclacel Pharmaceuticals, Delta‐Fly Pharma, Iterion Therapeutics, GlycoMimetics, and Regeneron Pharmaceuticals; and has received honoraria from Astex Pharmaceuticals. Gautam Borthakur has received research funding from Astex Pharmaceuticals, Ryvu Therapeutics, and PTC Therapeutics; has been a board of directors member or advisory committee member for Pacyclex Pharmaceuticals, Novartis, CytomX, and Bio Ascend; and has been a consultant for Catamaran Bio, AbbVie, PPD Development, Protagonist Therapeutics, and Janssen. Guillermo Garcia‐Manero has received research funding from Astex Pharmaceuticals, Novartis, AbbVie, BMS, Genentech, Aprea Therapeutics, Curis, and Gilead Sciences; has been a consultant for Astex Pharmaceuticals, Acceleron Pharma, and BMS; and has received honoraria from Astex Pharmaceuticals, Acceleron Pharma, AbbVie, Novartis, Gilead Sciences, Curis, Genentech, and BMS. Ghayas C. Issa received research funding from Celgene, Merck, Kura Oncology, Cullinan Oncology, Syndax, Astex, Novartis, Pupil Bio, Sumitomo, Daichi Sankyo, Crossbow; consultancy or advisory board fees from AbbVie, Novartis, Sanofi, AstraZeneca, Syndax, Kura Oncology, Biostate, Crossbow; and serves on the scientific advisory boards of Pupil Bio and Biostate. The other authors declare no conflicts of interest. Supporting information Supporting Information S1